• Thu news: Industry M&A volume down 8% over 2023. Pfizer’s Ibrance improves breast cancer survival. Lonza shedding capsule biz. AZ’s Lynparza in early breast cancer. Trump wants childhood vaccine discussion. See more on our front page

Restructuring in Rare Disease

Quote

anonymous

Guest
What's up with the restructuring in RD? Is DG and BF behind this initiative? Is this the same chaos that DG unleashed on vaccines? Management has said RD is the business unit to be. If so, then why restructure? Displacing everyone leads to loss of amazing talent that's not going to risk the perils of having to post for new positions and interviewing to keep their jobs. Beware of DG joining any franchise. Typical new management shortsightedness that doesn't understand the business or the structure to support the business.
 






Complete incompetence with new leadership in rare disease. DG was a disaster in vaccines and unfortunately she brought her incompetence to rare disease. Yesterday's call led by DG revealed she prefers to place blame on the disaster on others when it's her own incompetence. Please stop trying to cover up your own poor decision making and realize the only person that needs to go is yourself. Take ownership of your own disaster. Please don't show us photos of yourself with Warren Buffett anymore. You can't fake sell yourself to try and look like you're a Buffett. DG = total loser.
 






Have they announced anything else about this? Yesterday wasn’t really helpful except to hear that they have a crap contract with their dupi PSS - DC and DG didn’t say much about the restructure for Rare
 






Top Bottom
Back
Quote